And we revealed that ANKRD29 could be involved in tumor microenvironment (TME) and served as a promising biomarker of immune checkpoint blockers (ICBs) therapy in NSCLC by integrative bioinformatical analysis and T cell killing assays. Here, ANKRD29 is linked to neoplasm.